Log In
BCIQ
Print this Print this
 

CNTX-6016

  Manage Alerts
Collapse Summary General Information
Company Centrexion Therapeutics Corp.
DescriptionSelective cannabinoid CB2 receptor (CNR2) agonist
Molecular Target Cannabinoid CB2 receptor (CNR2)
Mechanism of ActionCannabinoid CB2 receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationPain
Indication DetailsTreat neuropathic pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/30/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today